December 12, 2017 / 6:37 AM / 2 years ago

BRIEF-Biotech Genmab sees 2018 expense growth of 40-50 pct

Dec 12 (Reuters) - FOLLOWING ARE STATEMENTS FROM GENMAB’S R’N’D UPDATE IN ATLANTA, GEORGIA:

* DENMARK’S GENMAB SEES 2018 EXPENSE GROWTH OF 40-50 PERCENT DRIVEN BY PIPELINE INVESTMENTS

* SAYS ROYALTY FUNDS 100 PCT OF EXPENSE INVESTMENT

* GENMAB TO CONDUCT NEW AND LARGER TISOTUMAB VEDOTIN TRIALS IN 2018

* SAYS 6 PRE-CLINICAL PRODUCTS RAPIDLY ADVANCING

* SAYS 2018 WILL BE 6TH YEAR OF PROFITABILITY SOURCE TEXT FOR MORE PRESENTATIONS: [IR.GENMAB.COM/EVENTS.CFM ] FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below